BRD7 and neoplasm: TP-472, which has less selectivity for BRD9 over BRD7 compared to other BRD9 inhibitors, blocked melanoma tumorigenicity and tumor growth in vivo [121] as well as suppressed the proliferation of uterine leiomyosarcoma cells [187].